[1]
van Heuvel Y, Schatz S, Rosengarten JF, Stitz J. Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. Toxins. 2022 Feb 14:14(2):. doi: 10.3390/toxins14020138. Epub 2022 Feb 14 [PubMed PMID: 35202165]
[2]
Meissner ME, Talledge N, Mansky LM. Molecular Biology and Diversification of Human Retroviruses. Frontiers in virology (Lausanne, Switzerland). 2022:2():. pii: 872599. doi: 10.3389/fviro.2022.872599. Epub 2022 Jun 2 [PubMed PMID: 35783361]
[3]
Aiken C, Rousso I. The HIV-1 capsid and reverse transcription. Retrovirology. 2021 Sep 25:18(1):29. doi: 10.1186/s12977-021-00566-0. Epub 2021 Sep 25 [PubMed PMID: 34563203]
[4]
Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. The New England journal of medicine. 1998 Jul 2:339(1):33-9 [PubMed PMID: 9647878]
[5]
Xu Y, Ollerton MT, Connick E. Follicular T-cell subsets in HIV infection: recent advances in pathogenesis research. Current opinion in HIV and AIDS. 2019 Mar:14(2):71-76. doi: 10.1097/COH.0000000000000525. Epub [PubMed PMID: 30585797]
[6]
Chadburn A, Abdul-Nabi AM, Teruya BS, Lo AA. Lymphoid proliferations associated with human immunodeficiency virus infection. Archives of pathology & laboratory medicine. 2013 Mar:137(3):360-70. doi: 10.5858/arpa.2012-0095-RA. Epub [PubMed PMID: 23451747]
[7]
Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Dec 6:73(11):e3572-e3605. doi: 10.1093/cid/ciaa1391. Epub [PubMed PMID: 33225349]
[8]
Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL, Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (London, England). 2002 Dec 14:360(9349):1921-6 [PubMed PMID: 12493258]
[9]
Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, Smith RD, Slack M, Delpech VC. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS (London, England). 2012 Jan 2:26(1):87-94. doi: 10.1097/QAD.0b013e32834dcf27. Epub [PubMed PMID: 22008657]
[10]
Saag MS. HIV Infection - Screening, Diagnosis, and Treatment. The New England journal of medicine. 2021 Jun 3:384(22):2131-2143. doi: 10.1056/NEJMcp1915826. Epub [PubMed PMID: 34077645]
[11]
Goldschmidt R, Chu C. HIV Infection in Adults: Initial Management. American family physician. 2021 Apr 1:103(7):407-416 [PubMed PMID: 33788514]
[12]
Burudpakdee C, Near AM, Tse J, Faccone J, Rodriguez PL, Karichu JK, Cheng MM. Real-world HIV diagnostic testing patterns in the United States. The American journal of managed care. 2022 Feb 1:28(2):e42-e48. doi: 10.37765/ajmc.2022.88826. Epub 2022 Feb 1 [PubMed PMID: 35139295]
[13]
Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection--United States, 2014. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2014 Apr 11:63(RR-03):1-10 [PubMed PMID: 24717910]
[14]
Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV medicine. 2017 Apr:18(4):256-266. doi: 10.1111/hiv.12421. Epub 2016 Aug 31 [PubMed PMID: 27578404]
[15]
Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N, Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV-positive individuals virally suppressed for }3 years with incomplete CD4 recovery. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 May:58(9):1312-21. doi: 10.1093/cid/ciu038. Epub 2014 Jan 22 [PubMed PMID: 24457342]
[16]
Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Mar 15:48(6):787-94. doi: 10.1086/597093. Epub [PubMed PMID: 19193107]
[17]
Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (London, England). 2000 Nov 25:356(9244):1800-5 [PubMed PMID: 11117912]
[18]
Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Sep 12:71(6):1379-1389. doi: 10.1093/cid/ciz999. Epub [PubMed PMID: 31606734]
[19]
Diaz RS, Hunter JR, Camargo M, Dias D, Galinskas J, Nassar I, de Lima IB, Caldeira DB, Sucupira MC, Schechter M. Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil. BMC infectious diseases. 2023 May 24:23(1):347. doi: 10.1186/s12879-023-08288-8. Epub 2023 May 24 [PubMed PMID: 37226112]
[20]
DeKoven S, Naccarato M, Brumme CJ, Tan DHS. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series. HIV medicine. 2023 Nov:24(11):1137-1143. doi: 10.1111/hiv.13520. Epub 2023 Jun 14 [PubMed PMID: 37317505]
[21]
Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, Shafer RW, Richman DD. 2022 update of the drug resistance mutations in HIV-1. Topics in antiviral medicine. 2022 Oct:30(4):559-574 [PubMed PMID: 36375130]
[22]
Margot NA, Wong P, Kulkarni R, White K, Porter D, Abram ME, Callebaut C, Miller MD. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. The Journal of infectious diseases. 2017 Mar 15:215(6):920-927. doi: 10.1093/infdis/jix015. Epub [PubMed PMID: 28453836]
[23]
Siedner MJ, Moosa MS, McCluskey S, Gilbert RF, Pillay S, Aturinda I, Ard K, Muyindike W, Musinguzi N, Masette G, Pillay M, Moodley P, Brijkumar J, Rautenberg T, George G, Gandhi RT, Johnson BA, Sunpath H, Bwana MB, Marconi VC. Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial. Annals of internal medicine. 2021 Dec:174(12):1683-1692. doi: 10.7326/M21-2229. Epub 2021 Oct 26 [PubMed PMID: 34698502]
[24]
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A, NADIA Trial Team. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. The lancet. HIV. 2022 Jun:9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20 [PubMed PMID: 35460601]
[25]
Blanco JL, Marcelin AG, Katlama C, Martinez E. Dolutegravir resistance mutations: lessons from monotherapy studies. Current opinion in infectious diseases. 2018 Jun:31(3):237-245. doi: 10.1097/QCO.0000000000000453. Epub [PubMed PMID: 29634660]
[26]
Patel DM, Moyo C, Bositis CM. A Review of the 2010 WHO Adult Antiretroviral Therapy Guidelines: Implications and Realities of These Changes for Zambia. Medical journal of Zambia. 2010:37(2):118-124 [PubMed PMID: 23193354]
[27]
. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision. 2010:(): [PubMed PMID: 23741771]